Tenaya TherapeuticsTNYA +2.13%32 EBITDA Margin % is -8,134.22% as of Mar. 2026. GuruFocus rates TNYA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 942 Biotechnology companies, Tenaya Therapeutics ranks worse than 96.5% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tenaya Therapeutics's EBITDA for the
three
months ended in Mar. 2026 was $-18.30 Mil. Tenaya Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $0.23 Mil. Therefore, Tenaya Therapeutics's EBITDA margin for the quarter that ended in Mar. 2026 was -8,134.22%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tenaya Therapeutics EBITDA Margin % Related Terms
Tenaya Therapeutics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tenaya Therapeutics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TNYA vs MIST, NRXP, TLSA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Tenaya Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenaya Therapeutics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tenaya Therapeutics (TNYA) has a EBITDA Margin % of -8,134.22% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tenaya Therapeutics and its competitors. According to the industry distribution chart, Tenaya Therapeutics ranks #909 out of 942 companies in the Biotechnology industry, placing it in the top 96.5%.
Is Tenaya Therapeutics' EBITDA Margin % too high?
Tenaya Therapeutics' current EBITDA Margin % is -8,134.22%. Based on the distribution chart, Tenaya Therapeutics ranks #909 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenaya Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' EBITDA Margin % compare to MIST and NRXP?
According to the Biotechnology industry distribution chart, Tenaya Therapeutics ranks #909 out of 942 companies for EBITDA Margin %. This places Tenaya Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tenaya Therapeutics and its competitors. Tenaya Therapeutics's current EBITDA Margin % is -8,134.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current EBITDA Margin % of -8,134.22%. The current EBITDA Margin % is -8,134.22%. Tenaya Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current EBITDA Margin % is -8,134.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score
Get the complete analysis for TNYA
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNYA has been successfully added to your 
